Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...

A toxin secreted by cholera bacteria can inhibit the growth of colorectal cancer without causing any measurable damage to the ...

For adults with atopic dermatitis (AD) receiving dupilumab treatment, a reversible lymphoid reaction (LR) has been observed, which mimics cutaneous T-cell lymphoma (CTCL), according to a study ...

Natural killer cells act as the immune system’s rapid-response team, but the stress of anxiety and insomnia may be quietly thinning their ranks. A study of young women in Saudi Arabia found that both ...

MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...

Lisocabtagene maraleucel is the first CAR T-cell therapy approved for relapsed or refractory MZL, expanding treatment options for this patient population. The TRANSCEND FL trial demonstrated a 95.5% ...

bDepartment of Lymphoma/State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research ...